Natera, Inc. ( NTRA) Q1 2026 Earnings Call May 7, 2026 4:30 PM EDT Ladies and gentlemen, welcome to Natera's First Quarter 2026 Financial Results Conference Call. As a reminder, this conference call ...
Greetings, and welcome to the Microchip's Q4 and Fiscal Year '26 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn ...
Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...
Women with endometriosis have an elevated risk of developing epithelial ovarian cancer, but, when they do develop it, they ...
Artificial intelligence shows promise for improving care for peripheral artery disease through earlier detection, improved ...
Background:Maternal chronic conditions are implicated as risk factors for congenital anomalies, but few studies have assessed ...
Background Cardiovascular disease and osteoarthritis (OA) share risk factors, but the link between comprehensive ...
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results